NCT03722459 is a NA clinical trial of MR Fingerprinting in Disease, sponsored by University of North Carolina, Chapel Hill.

Who is sponsoring NCT03722459?

NCT03722459 is sponsored by University of North Carolina, Chapel Hill.

What drugs are being tested in NCT03722459?

Interventions in NCT03722459: MR Fingerprinting.

Is NCT03722459 still recruiting?

NCT03722459 is currently completed. Last updated 20 December 2022.

Are results published for NCT03722459?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-12-20 · How we verify

NCT03722459

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel MRI Sequence- MR Fingerprinting

Completed NA Results posted Last updated 20 December 2022

What this trial tests

NA trial testing MR Fingerprinting in Disease in 22 participants. Completed in 9 September 2022.

Timeline

2 November 2018

Primary endpoint
9 September 2022

9 September 2022

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	22
Start date	2 November 2018
Primary completion	9 September 2022
Estimated completion	9 September 2022
Sites	1 location across United States

Drugs / interventions tested

MR Fingerprinting

Conditions studied

Disease — all drugs for Disease →

Sponsor

University of North Carolina, Chapel Hill

Who can join

Adults 18 to 99, any sex, with Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Magnetic Resonance Imaging (MRI) has become one of most important medical imaging tools over the past 30 years because it is non-invasive, requires no ionizing radiation, and provides exquisite images of soft tissues and anatomic structures with many tissue/disease specific contrasts. While MRI has served the community well for many years, it is increasingly clear that it also has significant limitations. One of the principle limitations is the lack of quantitative information for tissue/structure characterization. The current paradigm of MRI is to use a set of scanner settings to generate an image "weighted" by a specific MR contrast mechanism (physical parameter), where it is hoped that variations in the parameter will be accentuated. However, without quantitative knowledge of the parameters, the final image contrast may depend on many factors, which complicates image interpretation and diagnostic performance. Quantitative measurement can provide a great deal of information about tissue properties and pathological conditions, since these parameters ultimately determine the contrast that is observed in conventional images.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MR Fingerprinting

Trials testing the same drug.

NCT04851925 — MR Fingerprinting for Vestibular Schwannomas · unknown
NCT03800537 — MR Fingerprinting: A Novel Sequence Applied to Neuroimaging · NA · completed
NCT03846947 — Novel MRI Sequence MR Fingerprinting in Breast MRI Feasibility Study · NA · completed

Other recruiting trials for Disease

Currently open trials in the same condition.

NCT06271538 — Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome · Phase 4 · recruiting
NCT06081452 — Public Survey on Breath Testing for Health and Disease · recruiting
NCT06812091 — Human Microbiome Research and Development for Overcoming Pediatric Diseases · recruiting

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03722459 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
Last refreshed: 20 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03722459.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing